The renal effects of the water-soluble, non-folylpolyglutamate synthetase-dependent thymidylate synthase inhibitor ZD9331 in mice

British Journal of Cancer

Volumn 78, Issue 11, 1998, Pages 1457-1463

  Walton, M I ^a   Mitchell, F ^a   Aherne, G W ^a   Medlow, C J ^a   Boyle, F T ^b   Jackman, A L ^c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c NONE

Author keywords

Glomerular filtration rate; Pharmacokinetics; Thymidylate synthase inhibitor; ZD9331

Indexed keywords

INULIN; PLEVITREXED; THYMIDYLATE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; GLOMERULUS FILTRATION RATE; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; INULIN CLEARANCE; KIDNEY FUNCTION; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 0031771905     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.707     Document Type: Article

References (21)

1. 10 -propargyl-5,8-dideazafolic acid, CB3717. J Clin Oncol 4: 1245-1252
2. Clarke SJ, Jackman AI, and Judson IR (1993) The history of the development and clinical use of CB3717 and ICI D1644. In Proceedings of the International Symposium on Novel Approaches to Selective Treatments of Human Solid Tumours: Laboratory and Clinical Correlation. September 10-12, 1992, Buffalo, New York, Rustum Y (ed.), Adv Exptl Med Biol 339: pp. 277-287. Plenum Press: New York
3. Gibaldi M (1984) Biopharmaceutics and Clinical Pharmacokinetics. Lea and Febiger: Philadelphia
4. Gibson W, Bisset GMF, Marsham PR, Kelland LR, Judson IR and Jackman AL (1993) Measurement of polyglutamate metabolites of the thymidylate sythase inhibitor ICI D1694, in mouse and human cultured cells. Biochem Pharmacol 45: 863-869.
5. Harrap KR, Jackman AL, Newell DR, Taylor GA, Hughes LR and Calvert AH (1989) Thymidylate synthase: a target for anticancer drug design. Adv Enz Reg 29: 161-179
6. Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson IR and Hughes LR (1991) ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumour cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 51: 5579-5586
7. Jackman AL, Farrugia DC, Gibson W, Kimbell R, Harrap KR, Stephens TC, Azab M and Boyle FT (1995a) ZD1964 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Eur J Cancer 31A: 1277-1282
8. Jackman AL, Kelland LR, Kimbell R, Brown M, Gibson W, Aherne AW, Hardcastle A and Boyle FT (1995b) Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor, ZD1694 (Tomudex) in one mouse and three human cell lines. Br J Cancer 71: 914-924
9. Jackman AL, Boyle FT and Harrap KR (1996) Tomudex (ZD1694): from concept to care, a programme in rational drug discovery. Invest New Drugs 14: 305-316
10. Jackman AL, Kimbell R, Aherne GW, Brunton L, Jansen G, Stephens TC, Smith MN, Wardleworth MJ and Boyle FT (1997) The cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, non-polyglutamatable quinazoline-based inhibitor of thymidylate synthase. Clin Cancer Res 3: 911-921
11. Jennrich RI and Sampson PF (1968) Application of a stepwise regression to nonlinear estimation. Technometrics 10: 63-69
12. 10 -propargyl-5,8-dideazafolic acid (CB3717) and a non-nophrotoxic analogue ICI D1694, in mice. Br J Cancer 64: 833-838
13. Jodrell DI, Newell DR, Gibson W, Hughes LR and Calvert AH (1991b) The pharmacokinetics of the quinazoline antifolate ICI D1694 in mice and rats. Cancer Chemother Pharmacol 28: 331-338
14. Jones TR, Thornton TJ, Flinn A, Jackman AL, Newell DR and Calvert AH (1989) Quinazoline antifolates inhibiting thymidylate synthase: 2-desamino derivatives with enhanced solubility and potency. J Med Chem 32: 847-852
15. 10 -propargyl-5,8-dideazafolic acid (CB3717) in the mouse. Cancer Treat Rep 70: 971-979
16. Ratain MJ, Cooper N, Smith R, Vogelzang NJ, Mani S, Shulman K, Lowe PG and Averbuch SD (1997) Phase I study of ZD9331: a novel thymidylate synthase (TS) inhibitor. Proc Am Soc Clin Oncol 16: 729
17. Rees C, Judson I, Beale P, Mitchell F, Smith R, Mayne K, Averbuch S and Jackman AL (1997) Phase I trial of ZD9331, a non-polyglutamatable thymidylate synthase inhibitor given as a five-day continuous infusion. Proc Am Soc Clin Oncol 16: 730
18. Stephens TC, Smith MN, McCloskey ML, Waterman SE, Gwynne AJ, Valcaccia BE, Jackman AL, Wardleworth JM and Boyle FT (1994) ZD9331, a novel non-polyglutamated thymidylate sythase inhibitor: in vivo antitumour efficacy and toxicity to normal murine tissues. Proc Am Assoc Cancer Res 35: 305
19. 10-propargyl-5,8-dideazafolic acid. Eur J Cancer Clin Oncol 24: 201
20. Wagner JG (1975) Clinical Pharmacokinetics. Drug Intelligence Publications: Hamilton
21. Walton MI, Gibson W, Aherne GW, Lawrence N, Stephens TC, Smith MN and Jackman AL (1996) Preclinical pharmacology of Cb300900, a novel dipeptide inhibitor of tymidylate synthase in mice. J Pharmacol Exp Ther 277: 909-916